公开(公告)号：US12071633B2

公开(公告)日：2024-08-27

申请号：US17500898

申请日：2021-10-13

Applicant: KRIYA THERAPEUTICS, INC.

Inventor： Brian Furmanski ,  Nachiketa Gupta ,  Bruce Schnepp ,  Michele Stone

IPC: C12N15/86 ,  A61K38/20 ,  A61K39/395 ,  A61P35/00

CPC classification number: C12N15/86 ,  A61K38/208 ,  A61K39/3955 ,  A61P35/00 ,  C12N2750/14132 ,  C12N2750/14143 ,  C12N2750/14171 ,  C12N2830/008 ,  C12N2840/203

Abstract: The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.

公开(公告)号：US20240238377A1

公开(公告)日：2024-07-18

申请号：US18628835

申请日：2024-04-08

Applicant: UNIVERSITAT ZURICH

Inventor： Burkhard BECHER ,  Johannes VOM BERG

IPC: A61K38/20 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28

CPC classification number: A61K38/208 ,  A61K9/0019 ,  A61K9/0085 ,  A61K39/39516 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/5434 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2319/30

Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.

公开(公告)号：US20240099973A1

公开(公告)日：2024-03-28

申请号：US17763996

申请日：2020-09-25

Applicant: LONZA SALES AG

Inventor： Conlin O'NEIL ,  Raymond BOURDEAU

IPC: A61K9/127 ,  A61K31/7088 ,  A61K38/20 ,  A61K47/02 ,  A61K47/26 ,  A61K47/69

CPC classification number: A61K9/127 ,  A61K31/7088 ,  A61K38/208 ,  A61K47/02 ,  A61K47/26 ,  A61K47/6911

Abstract: The present disclosure relates to compositions for the storage and administration of extracellular vesicles (e.g., exosomes) that can comprise a scaffold protein and one or more (e.g., 1, 2, 3, 4, 5 or more) exogenous biologically active moieties. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent a range of medical disorders.

公开(公告)号：US11884727B2

公开(公告)日：2024-01-30

申请号：US17186960

申请日：2021-02-26

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61P25/28 ,  A61P37/02 ,  A61K38/00 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/4155 ,  A61K38/02 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K38/208 ,  A61K2300/00 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US11884717B2

公开(公告)日：2024-01-30

申请号：US17226506

申请日：2021-04-09

Applicant: The Brigham and Women's Hospital, Inc. ,  The Broad Institute, Inc. ,  Massachusetts Institute of Technology

Inventor： Vijay K. Kuchroo ,  Chao Wang ,  Aviv Regev ,  Karthik Shekhar

IPC: A61K38/20 ,  A61K38/17 ,  C07K14/705 ,  A61P37/00 ,  A61P1/00 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  C07K14/54 ,  C07K16/24 ,  C07K16/28 ,  C12N15/113 ,  A61K39/00

CPC classification number: C07K14/70596 ,  A61K38/177 ,  A61K38/1709 ,  A61K38/208 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P35/00 ,  A61P37/00 ,  C07K14/5434 ,  C07K16/244 ,  C07K16/2896 ,  C12N15/1136 ,  C12N15/1138 ,  A61K2039/575 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/20 ,  A61K38/208 ,  A61K38/1709

Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.

公开(公告)号：US20230272041A1

公开(公告)日：2023-08-31

申请号：US17920174

申请日：2021-04-22

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Mitchell Bigelow ,  Alexandra Braun ,  Ann F. Cheung ,  Jean-Marie Cuillerot ,  Mark Derose ,  Asya Grinberg ,  Eva Gutierrez ,  Patrick Kirby ,  Christopher Ryan Morgan ,  Michael C. Naill ,  Steven O'Neil ,  Michael Shifrin ,  Nicolai Wagtmann

IPC: C07K14/735 ,  A61K31/7016 ,  A61K47/14 ,  A61K9/00 ,  A61P35/04 ,  C07K16/28 ,  A61K38/20 ,  A61K9/19

CPC classification number: C07K14/70535 ,  A61K31/7016 ,  A61K47/14 ,  A61K9/0019 ,  A61P35/04 ,  C07K16/2896 ,  A61K38/208 ,  A61K9/19

Abstract: The present invention relates to pharmaceutical formulations for heterodimeric Fc-fused proteins which are advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are dosage regimens for such heterodimeric Fc-fused proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.

公开(公告)号：US11739302B2

公开(公告)日：2023-08-29

申请号：US16926803

申请日：2020-07-13

Applicant: Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.

Inventor： Ming Yuan

IPC: C12N15/863 ,  C12N7/00 ,  A61K9/00 ,  A61K39/395 ,  G01N33/50 ,  C12Q1/02 ,  G01N33/574 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K35/768 ,  A61P35/00 ,  A61K31/505 ,  A61K38/20 ,  A61K47/00 ,  A61K39/00

CPC classification number: C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/505 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K35/768 ,  A61K38/208 ,  A61K38/2013 ,  A61K39/3955 ,  A61K47/00 ,  A61P35/00 ,  C12Q1/02 ,  G01N33/5005 ,  G01N33/57407 ,  A61K2039/5252 ,  C12N2710/24121 ,  C12N2710/24132

Abstract: An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.

公开(公告)号：US20230263743A1

公开(公告)日：2023-08-24

申请号：US18311114

申请日：2023-05-02

Applicant: Suntec Medical, Inc.

Inventor： Chun-Ting Cheng ,  Cheng-Ying Hsieh ,  Chi-Feng Lin ,  Kuan-Yu Lin ,  Chao-Ming Su ,  Pauline Ying Lau

IPC: A61K9/51 ,  C07K16/32 ,  C07K16/28 ,  C07K16/22 ,  C07K16/18 ,  A61K38/20 ,  A61K38/21 ,  A61K38/19

CPC classification number: A61K9/5146 ,  C07K16/32 ,  C07K16/2881 ,  C07K16/2863 ,  C07K16/22 ,  C07K16/18 ,  A61K38/208 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/2086 ,  A61K38/20 ,  A61K38/212 ,  A61K38/217 ,  A61K38/191 ,  A61K9/5123 ,  A61K9/5192

Abstract: The present invention is directed to nanoparticles comprising: (a) an inner core comprising oligomeric (−)-epigallocatechin gallate (OEGCG), (b) an outer core comprising a polyethylene glycol-epigallocatechin gallate conjugate (PEG-EGCG), and (c) a protein molecule of a drug substance encapsulated in the inner core; wherein at least 70% of the nanoparticles have a diameter between 50-300 nm. The present invention also provides a process for preparing the nanoparticles. The present invention further provides a method of treating cancer by administering to a subject in need thereof the nanoparticles of the present invention, in an amount effective to treat cancer.

公开(公告)号：US20230203118A1

公开(公告)日：2023-06-29

申请号：US18056375

申请日：2022-11-17

Applicant: Jinyu Zhang

Inventor： Jinyu ZHANG

IPC: C07K14/54 ,  A61P35/00 ,  C07K14/52 ,  C07K14/535 ,  C07K14/55 ,  A61K38/20 ,  A61K38/19 ,  A61P35/04

CPC classification number: C07K14/5434 ,  A61P35/00 ,  C07K14/52 ,  C07K14/535 ,  C07K14/54 ,  C07K14/55 ,  A61K38/208 ,  A61K38/193 ,  A61P35/04 ,  A61K9/0014

Abstract: Provided is a cytokine combination for treating a tumor and/or preventing recurrence or metastasis of the tumor. The cytokine combination comprising at least three cytokines selected from the following groups: IL12 or a functional variant thereof, GMCSF or a functional variant thereof, FLT3L or a functional variant thereof, IL2 or a functional variant thereof, IL15 or a functional variant thereof, IL21 or a functional variant thereof, and IL7 or a functional variant thereof. Also provided is a nucleic acid molecule encoding the cytokine combination and a vector thereof, a cell, a pharmaceutical composition, and a application thereof for the manufacture of a drug for treating the tumor and/or preventing recurrence or metastasis of the tumor.

公开(公告)号：US20190248901A1

公开(公告)日：2019-08-15

申请号：US16343664

申请日：2017-10-19

Applicant: Novelogics Biotechnology Inc.

Inventor： Ian Wayne CHENEY

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2833 ,  A61K38/19 ,  A61K38/208 ,  A61K38/2086 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: This present disclosure relates to antibodies which bind to soluble forms of MICA and/or MICB protein, compositions comprising the antibodies, and use of the antibodies for diagnostics and in treatment of diseases characterized by elevated level of a MIC protein.